12:00 AM
 | 
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Phase III discontinued

Celgene discontinued the open-label, international Phase III ORIGIN (CLL-008) trial in 450 elderly patients with previously untreated B cell CLL after an imbalance in the number of deaths was observed in patients treated with Revlimid compared to chlorambucil. Specifically, there were 34 deaths out of 210 patients in the Revlimid arm compared to 18 deaths...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >